In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
RXRX has reported updated data from its ELUCIDATE and TUPELO trials, but the stock has failed to mount a sustained rally. The ELUCIDATE update provides just an additional 10 patients of data treated ...
This widely used method of calculating returns considers a portfolio's cash flows Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results